DEBRA NARCISSE: Open Payments
NPI 1306039623 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,051 in 56 payments from 19 companies in 2025. Trend: 2023 $527 · 2024 $1,595 · 2025 $2,051
Food & beverage: $2,051
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $342 |
| Lilly USA, LLC | 10 | $295 |
| PFIZER INC. | 4 | $162 |
| Madrigal Pharmaceuticals | 2 | $162 |
| Medtronic, Inc. | 1 | $150 |
| AstraZeneca Pharmaceuticals LP | 4 | $149 |
| Neurocrine BioSciences, Inc. | 1 | $119 |
| ABIOMED | 1 | $114 |
| Phathom Pharmaceuticals, Inc. | 1 | $101 |
| Lundbeck LLC | 4 | $84 |
Products named: ZEPBOUND, REZDIFFRA, Wegovy, INTERSTIM, NURTEC ODT, AIRSUPRA, REXULTI, VOQUEZNA.
Industry payments across NY — which companies pay providers there.
